Association between delayed methotrexate metabolism, coagulation function, and adverse reactions in patients with acute lymphoblastic leukemia receiving high-dose methotrexate treatment.

ABSTRACT:

Objective

This study aimed to identify the risk factors associated with delayed drug metabolism during high-dose methotrexate (HD-MTX) therapy and to analyze the relationship between delayed metabolism and post-treatment toxic adverse effects.

Methods

A retrospective analysis was performed on 189 patients with acute lymphoblastic leukemia who received HD-MTX therapy at Xi'an Gaoxin Hospital between February 2018 and May 2023. Serum MTX concentrations were measured at 24, 48, and 72 hours after each HD-MTX administration (cycle), with a 48-hour concentration ≥ 1 μmol/L defining delayed metabolism on a per-cycle basis. Clinical characteristics and laboratory parameters were collected, and univariate and multivariate logistic regression analyses were conducted using SPSS versio

SUBMITTER: Xu J 

PROVIDER: S-EPMC12808053 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature